Areas of Focus:

Academia–Industry PartnershipsAnimal ModelsBiological & MechanisticBiomarker DiscoveryCollaboration & InnovationCross-institutional CollaborationData-Driven & QuantitativeExperimental Platforms & ModelsIn Vitro ModelsInnate ImmunityMulti-omics IntegrationNeuro-Immune InteractionsPrecision MedicineSingle Cell TechnologiesSpatial BiologyTherapeutic DevelopmentTranslational & ClinicalNeurologic DiseasesOther
  • Dr. Harry M. Zimmerman and Dr. Nicholas and Viola Spinelli Professor of Neurology and Neuroscience, Department of Neurology (Memory Disorders), Yale School of Medicine, Yale University
  • Vice Chair for Research, Department of Neurology, Yale School of Medicine, Yale University
  • Director, Center for Experimental Neuroimaging, Yale School of Medicine, Yale University

Dr. Jaime Grutzendler is the Dr. Harry M. Zimmerman and Dr. Nicholas and Viola Spinelli Professor of Neurology and Neuroscience, Vice Chair for Research in Neurology, and Director of the Center for Experimental Neuroimaging at Yale School of Medicine. He is a leader in developing and applying live optical imaging approaches to study the brain, including high-resolution intravital two-photon imaging, optical electrophysiology, expansion microscopy, spatial and proximity labeling proteomics, and molecular therapeutic strategies.

Dr. Grutzendler’s laboratory investigates cellular and molecular mechanisms of brain function and neuropathology, with emphasis on neurodegeneration, neurovascular injury, and neuroimmune interactions. Current work focuses on Alzheimer’s disease, vascular cognitive impairment, amyloid-associated axonal and myelin pathology, and vascular remodeling after microvascular injury. His research program also seeks to translate mechanistic discoveries into therapeutic approaches, including strategies for cell type-selective delivery of drugs, nucleic acids, and molecular probes to the central nervous system and retina.

Through the Colton Consortium, Dr. Grutzendler’s group aims to bring concepts from autoimmunity into neurovascular biology, with particular focus on autoantibody-mediated vascular injury, microvascular occlusion, thrombosis, and antiphospholipid syndrome.

Projects

Featured Pilot Projects

Therapeutic Targeting of Thromboangioplasticity in Autoimmune Antiphospholipid Syndrome
Project | Yale University

Therapeutic Targeting of Thromboangioplasticity in Autoimmune Antiphospholipid Syndrome

Restoring thromboangioplasticity in antiphospholipid syndrome by developing recombinant proteins that counteract harmful anti-annexin V antibodies.